Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity for weight loss, doctors are observing a ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Exxon Mobil ...

GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...

Insiya Klapper, who lives in the Capital Region, has experienced a transformative year, shedding 60 pounds with the help of the GLP-1 medic ...